VOLUME ALERT: Map Pharmaceuticals (MAPP, AZN)

Posted in General 
July 9th, 2009

MAP Pharmaceuticals Inc. (Nasdaq: MAPP) shares are down about 9 percent near $10, on opening volume of about 30,000 shares. The stock is reacting to plans to suspend its asthma drug candidate Unit Dose Budesonide, after licensing partner AstraZeneca (NYSE: AZN) decided to end a collaboration agreement.  — Mike Tarsala

Comments are closed